<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>1077</number>
    <updateDate>2023-01-11T13:27:26Z</updateDate>
    <updateDateIncludingText>2023-01-11T13:27:26Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <type>S</type>
    <introducedDate>2015-04-23</introducedDate>
    <congress>114</congress>
    <committees>
      <item>
        <systemCode>sshr00</systemCode>
        <name>Health, Education, Labor, and Pensions Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Reported by</name>
            <date>2016-04-05T20:24:45Z</date>
          </item>
          <item>
            <name>Markup by</name>
            <date>2016-03-09T15:00:00Z</date>
          </item>
          <item>
            <name>Referred to</name>
            <date>2015-04-23T19:50:37Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to authorize priority review for breakthrough devices.</title>
        <congress>114</congress>
        <number>2337</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2015-05-15</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>21st Century Cures Act</title>
        <congress>114</congress>
        <number>34</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2016-12-13</actionDate>
          <text>Became Public Law No: 114-255.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2016-04-05</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 412.</text>
        <type>Calendars</type>
      </item>
      <item>
        <actionDate>2016-04-05</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2016-04-05</actionDate>
        <text>Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.</text>
        <type>Committee</type>
        <actionCode>14000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2016-03-09</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2015-04-23</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2015-04-23</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>B001135</bioguideId>
        <fullName>Sen. Burr, Richard [R-NC]</fullName>
        <firstName>Richard</firstName>
        <lastName>Burr</lastName>
        <party>R</party>
        <state>NC</state>
        <middleName>Mauze</middleName>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>B001267</bioguideId>
        <fullName>Sen. Bennet, Michael F. [D-CO]</fullName>
        <firstName>Michael</firstName>
        <lastName>Bennet</lastName>
        <party>D</party>
        <state>CO</state>
        <sponsorshipDate>2015-04-23</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>H000338</bioguideId>
        <fullName>Sen. Hatch, Orrin G. [R-UT]</fullName>
        <firstName>ORRIN</firstName>
        <lastName>HATCH</lastName>
        <party>R</party>
        <state>UT</state>
        <middleName>GRANT</middleName>
        <sponsorshipDate>2015-04-23</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>D000607</bioguideId>
        <fullName>Sen. Donnelly, Joe [D-IN]</fullName>
        <firstName>Joe</firstName>
        <lastName>Donnelly</lastName>
        <party>D</party>
        <state>IN</state>
        <sponsorshipDate>2015-10-20</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <cboCostEstimates>
      <item>
        <pubDate>2016-06-28T11:58:00Z</pubDate>
        <title>S. 1077, Advancing Breakthrough Devices for Patients Act of 2016</title>
        <url>https://www.cbo.gov/publication/51719</url>
        <description>As reported by the Senate Committee on Health, Education, Labor, and Pensions on April 5,&amp;nbsp;2016</description>
      </item>
    </cboCostEstimates>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Health technology, devices, supplies</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2015-04-23</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2016-03-09T20:01:02Z</updateDate>
        <text><![CDATA[ <p><b>Advancing Breakthrough Devices for Patients Act of 2015</b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to expand the Food and Drug Administration's (FDA's) priority review of breakthrough medical devices to include all classes of devices. Currently, only class III (new or highest risk) devices are eligible.</p> <p>Upon a sponsor's request, the FDA must determine whether a device meets the criteria for priority review as a breakthrough device.</p> <p>To expedite the development and review of designated medical devices, the FDA must:</p> <ul> <li>assign a team of staff for each device, </li> <li>adopt an efficient process for dispute resolution, </li> <li>provide for interactive and timely communication with the device sponsor, </li> <li>expedite review of manufacturing and quality systems compliance, </li> <li>disclose to the sponsor in advance the topics of any consultation between the FDA and external experts or an advisory committee and provide the sponsor the opportunity to recommend external experts, </li> <li>assign staff to address questions by institutional review committees concerning investigational use of the device. </li></ul>The FDA may: (1) coordinate with the sponsor regarding early agreement on a data development plan; (2) take steps to ensure that the design of clinical trials is as efficient as practicable; (3) utilize timely postmarket data collection; and (4) agree to clinical protocols, subject to a decision that a substantial scientific issue essential to determining the safety or effectiveness of the device exists.]]></text>
      </summary>
      <summary>
        <versionCode>01</versionCode>
        <actionDate>2016-04-05</actionDate>
        <actionDesc>Reported to Senate with amendment(s)</actionDesc>
        <updateDate>2016-12-09T22:28:45Z</updateDate>
        <text><![CDATA[ <p><b>Advancing Breakthrough Devices for Patients Act of 2016</b></p> <p>(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to revise requirements regarding priority review of breakthrough medical devices.</p> <p>Upon a sponsor's request, the Food and Drug Administration (FDA) must determine whether a device meets the criteria for designation as a breakthrough device. To expedite the development and review of designated medical devices, the FDA must:</p> <ul> <li>assign a team of staff for each device, </li> <li>adopt an efficient process for dispute resolution, </li> <li>provide for interactive and timely communication with the device sponsor, </li> <li>expedite review of manufacturing and quality systems compliance, </li> <li>disclose to the sponsor in advance the topics of any consultation between the FDA and external experts or an advisory committee and provide the sponsor the opportunity to recommend external experts, </li> <li>assign staff to address questions by institutional review committees concerning investigational use of the device. </li></ul> <p>The FDA may: (1) coordinate with the sponsor regarding early agreement on a data development plan; (2) take steps to ensure that the design of clinical trials is as efficient and flexible as practicable; (3) utilize timely postmarket data collection; and (4) agree to clinical protocols, subject to a decision that a substantial scientific issue essential to determining the safety or effectiveness of the device exists. </p> <p>The FDA must issue guidance and report on this priority review process.</p>]]></text>
      </summary>
    </summaries>
    <title>Advancing Breakthrough Devices for Patients Act of 2016</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Advancing Breakthrough Devices for Patients Act of 2016</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to provide for expedited development of and priority review for breakthrough devices.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Advancing Breakthrough Devices for Patients Act of 2015</title>
      </item>
      <item>
        <titleType>Short Titles as Reported to Senate</titleType>
        <title>Advancing Breakthrough Devices for Patients Act of 2016</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Reported to Senate</type>
        <date>2016-04-05T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-114s1077rs/xml/BILLS-114s1077rs.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Introduced in Senate</type>
        <date>2015-04-23T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-114s1077is/xml/BILLS-114s1077is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2016-04-05</actionDate>
      <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 412.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
